Literature DB >> 24252097

Aplasia cutis congenita with dystrophic epidermolysis bullosa: clinical and mutational study.

C Chiaverini1, A Charlesworth, A Fernandez, S Barbarot, D Bessis, C Bodemer, A-C Bursztejn, A-M Cobo, M Del Rio, M D'Incan, C Labrèze, C Langlet, J Mazereeuw, J Miquel, P Vabres, G Meneguzzi, J-P Lacour.   

Abstract

BACKGROUND: Aplasia cutis congenita (ACC) has been associated with all clinical forms of inherited epidermolysis bullosa (EB), including dominant and recessive dystrophic EB (DDEB and RDEB). To date, only a few patients with DEB specifically combined with ACC have been described and genotyped and almost all cases represent dominant forms of the condition.
OBJECTIVES: The aim of this study was to describe new mutations of COL7A1 in patients with DEB and ACC and investigate possible genotype-phenotype correlations.
METHODS: Twenty-two patients with DEB and ACC were included among the 123 patients with DEB whose COL7A1 mutations have been identified in the Reference Centre in Nice.
RESULTS: Seven patients presented a severe generalized RDEB phenotype (RDEB-sev-gen), while the other 15 suffered from milder phenotypes. We identified 28 mutations in COL7A1, of which nine are novel. Patients with severe phenotypes have mostly mutations leading to premature termination codon (PTC) and/or splice-site or missense mutations. Patients with the milder phenotypes have mostly glycine or arginine substitutions associated or not with other types of mutations. All amino acid substitutions fell within the carboxyl portion of the triple helix domain (THD) of collagen VII, close to the THD interruptions.
CONCLUSIONS: Our findings suggest that ACC is a frequent manifestation in patients with DEB irrespective of the severity of the disease, and is due to leg rubbing in utero. In children with a moderate form of DEB with no or moderate skin fragility, a glycine substitution near the THD interruption domain of the collagen VII leading to thermolabile protein could explain this phenomenon.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24252097     DOI: 10.1111/bjd.12741

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

1.  Cord blood platelet gel treatment of dystrophic recessive epidermolysis bullosa.

Authors:  Gianluca Tadini; Lidia Pezzani; Stefano Ghirardello; Paolo Rebulla; Susanna Esposito; Fabio Mosca
Journal:  BMJ Case Rep       Date:  2015-01-08

Review 2.  A practical approach to the evaluation and treatment of an infant with aplasia cutis congenita.

Authors:  S R Humphrey; X Hu; K Adamson; A Schaus; J N Jensen; B Drolet
Journal:  J Perinatol       Date:  2017-10-19       Impact factor: 2.521

3.  Topical ropivacaine for analgesia of aplasia cutis congenita in newborns with hereditary epidermolysis bullosa.

Authors:  A Chambelland; C Devos; F Casagrande; C Chiaverini
Journal:  Orphanet J Rare Dis       Date:  2020-12-01       Impact factor: 4.123

4.  Epidermolysis Bullosa With Congenital Absence of Skin: Congenital Corneal Cloudiness and Esophagogastric Obstruction Including Extended Genotypic Spectrum of PLEC, LAMC2, ITGB4 and COL7A1.

Authors:  Pharuhad Pongmee; Sanchawan Wittayakornrerk; Ramrada Lekwuttikarn; Sasikarn Pakdeeto; Piangor Watcharakuldilok; Chatchay Prempunpong; Thipwimol Tim-Aroon; Chawintee Puttanapitak; Piyawan Wattanasoontornsakul; Thitiporn Junhasavasdikul; Parith Wongkittichote; Saisuda Noojarern; Duangrurdee Wattanasirichaigoon
Journal:  Front Genet       Date:  2022-04-01       Impact factor: 4.772

5.  Case Report: Uncommon Association of ITGB4 and KRT10 Gene Mutation in a Case of Epidermolysis Bullosa With Pyloric Atresia and Aplasia Cutis Congenita.

Authors:  Melinda Matyas; Diana Miclea; Gabriela Zaharie
Journal:  Front Genet       Date:  2021-07-08       Impact factor: 4.599

6.  Type VI Aplasia Cutis Congenita: Bart's Syndrome.

Authors:  Ferit Kulalı; Ahmet Yagmur Bas; Yusuf Kale; Istemi Han Celik; Nihal Demirel; Sema Apaydın
Journal:  Case Rep Dermatol Med       Date:  2015-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.